In 2022, the global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market was valued at US$ 2.54 billion, and is poised for substantial growth. Forecasts predict that the market will expand to US$ 3.5 billion by 2023 and is projected to reach an impressive US$ 6.82 billion by 2033, maintaining a steady CAGR of 6.9% from 2023 onwards. This remarkable trajectory is primarily attributed to advancements in technology and the escalating demand for personalized treatment options. Notably, from 2018 to 2022, the CAR T-cell therapy market witnessed a robust growth at a CAGR of 7%.